发明公开
- 专利标题： HETEROARYL SODIUM CHANNEL INHIBITORS
- 专利标题（中）： 杂芳基NATRIUMKANALHEMMER
-
申请号： EP12756842.6申请日： 2012-08-16
-
公开(公告)号： EP2744805A1公开(公告)日： 2014-06-25
- 发明人: DINEEN, Thomas , MARX, Isaac, E. , NGUYEN, Hanh, Nho , WEISS, Matthew
- 申请人： Amgen Inc.
- 申请人地址： One Amgen Center Drive Thousand Oaks, California 91320-1799 US
- 专利权人： Amgen Inc.
- 当前专利权人： Amgen Inc.
- 当前专利权人地址： One Amgen Center Drive Thousand Oaks, California 91320-1799 US
- 代理机构： HOFFMANN EITLE
- 优先权： US201161524691P 20110817
- 国际公布： WO2013025883 20130221
- 主分类号： C07D403/14
- IPC分类号： C07D403/14 ; C07D417/12 ; C07D417/14 ; A61K31/404 ; A61K31/4184 ; A61P29/00
摘要：
The present invention provides compounds of Formula I or II, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
信息查询
